quest
clinic
candid
counteract
immun
activ
becom
hot
topic
aid
research
hiv
infect
character
malign
immun
hyperactiv
correl
diseas
progress
poor
respons
antiretrovir
therapi
art
moreov
immun
hyperactiv
also
regard
major
obstacl
cure
aid
begin
millennium
articl
author
one
us
launch
chloroquin
tool
inhibit
viral
replic
relat
malign
immun
activ
associ
viral
diseas
articl
spark
new
wave
studi
extend
theori
previous
design
hivaid
viral
diseas
character
excess
immun
activ
discuss
accumul
acid
organel
chloroquin
exert
direct
antivir
effect
envelop
virus
decreas
activ
sever
cell
type
involv
immun
respons
chloroquin
sinc
shown
promis
preclin
studi
vitro
vivo
therapeut
agent
emerg
virus
mer
cov
note
chloroquin
indic
promis
candid
filoviru
treatment
especi
latest
ebola
epidem
two
studi
three
chloroquin
show
antivir
activ
mice
maximum
toler
dose
thu
render
drug
interest
agent
test
combin
antiebola
therapi
howev
effect
chloroquin
hydroxyl
analogu
hydroxychloroquin
hiv
infect
ie
initi
target
repurpos
drug
remain
controversi
one
hand
base
result
earlier
clinic
trial
chloroquinehydroxychloroquin
recent
resuggest
promis
candid
restrict
hivrel
immun
activ
hand
result
latest
clinic
trial
indic
chloroquinehydroxychloroquin
benefici
effect
immun
activ
provid
state
art
studi
investig
use
chloroquinehydroxychloroquin
therapeut
tool
hivaid
suggest
possibl
biolog
ground
clinic
result
obtain
moreov
describ
reason
group
decid
proceed
strategi
base
anoth
drug
ie
auranofin
share
chloroquin
antirheumat
effect
sever
review
recent
publish
immun
activ
hiv
infect
briefli
immun
hyperactiv
commonli
measur
express
level
peripher
blood
lymphocyt
marker
hladr
correl
also
predict
diseas
progress
review
immun
activ
gradual
decreas
follow
therapi
initi
maintain
high
immunolog
nonrespond
individu
maintain
low
count
despit
prolong
exposur
art
initi
studi
focus
relationship
diseas
progress
activ
tcell
later
studi
better
conclud
broader
relationship
diseas
progress
immun
hyperactiv
involv
also
tcell
innat
immun
immun
activ
viral
replic
believ
mutual
enhanc
viciou
circl
viru
recogn
immun
system
nonself
induc
immun
activ
turn
fuel
viral
replic
furnish
viru
materi
synthes
differ
viral
compon
exampl
lymphocyt
activ
increas
cytoplasm
level
deoxyribonucleotid
necessari
viral
dna
synthesi
revers
transcriptas
viciou
circl
may
still
persist
anatom
compart
incomplet
penetr
art
hivinduc
immun
activ
limit
specif
immun
exert
effect
innat
immun
well
shown
activ
plasmacytoid
dendrit
cell
pdc
differ
myeloid
dendrit
cell
potent
antigenpres
cell
bodi
induc
innat
antimicrobi
immun
produc
type
interferon
figur
pdc
intern
viral
interact
intern
viru
activ
cell
mainli
tolllik
receptor
signal
figur
compar
patholog
corrobor
hypothesi
overstimul
pathway
may
associ
deleteri
effect
sooti
mangabey
cercocebu
ati
infect
simian
homolog
hiv
ie
simian
immunodefici
viru
siv
develop
aid
display
weak
product
upon
stimul
antagonist
contrari
rhesu
macaqu
macaca
mulatta
progress
aid
produc
high
amount
pdc
subject
stimuli
moreov
anoth
speci
display
nonpathogen
siv
infect
ie
african
green
monkey
chlorocebu
aethiop
character
effici
control
product
follow
acut
infect
pdc
decreas
peripher
blood
progress
aid
upon
activ
migrat
lymphoid
tissu
huge
number
cell
resid
gutassoci
lymphoid
tissu
galt
accord
microbi
transloc
theori
intestin
mucosa
damag
consequ
inflamm
may
becom
permeabl
product
gut
microbiom
enhanc
hivrel
immun
hyperactiv
final
immun
activ
one
primari
driver
gener
mainten
viral
reservoir
mainli
constitut
latent
infect
central
transit
memori
tcell
henceforth
tcm
ttm
respect
also
case
compar
patholog
provid
clue
understand
phenomenon
shown
tcm
cell
sooti
mangabey
express
upon
activ
low
level
main
coreceptor
viru
entri
cell
thu
limit
infect
import
cellular
compart
instead
activ
tcm
cell
aidsdevelop
speci
human
rhesu
macaqu
upregul
level
higher
extent
cell
sooti
mangabey
thu
facilit
gener
consist
viral
reservoir
cell
becom
quiescent
viral
replic
switch
latent
infect
hivreservoir
cell
prolifer
lowlevel
antigen
stimul
tcm
homeostat
prolifer
ttm
process
enhanc
gener
immun
activ
multipl
vitro
effect
chloroquin
could
support
possibl
use
modul
immun
activ
hivaid
chloroquin
hydroxyl
analogu
hydroxychloroquin
shown
sever
studi
inhibit
replic
review
effect
quinolin
mainli
due
induct
defect
matur
viral
envelop
glycoprotein
might
mimic
effect
broadli
neutral
antibodi
direct
viral
envelop
although
effect
antibodi
weaker
direct
site
effect
addit
nonnucleosid
revers
transcriptas
inhibitor
nnrti
synergist
proteas
inhibitor
pi
quinolin
drug
accumul
lymphoid
tissu
might
decreas
ongo
viral
replic
art
anatom
sanctuari
consequ
switch
one
main
driver
immun
activ
chloroquin
also
inhibitor
pglycoprotein
pgp
multidrug
resist
protein
mrp
cell
surfac
glycoprotein
extrud
sever
antiretrovir
drug
extracellular
medium
line
evid
chloroquin
shown
increas
intracellular
level
pi
effect
chloroquin
combin
nrti
instead
controversi
report
addit
effect
other
detect
combin
effect
chloroquin
integras
inhibitor
yet
unknownchloroquin
accumul
phagosom
pdc
inhibit
hivinduc
activ
might
therefor
impact
innat
immunityinduc
immun
hyperactivationa
recent
studi
show
hydroxychloroquin
select
induc
apoptosi
memori
tcell
compart
upon
activ
tcell
acquir
phenotyp
antimemori
effect
limit
immun
activ
figur
grow
consensu
induct
apoptosi
memori
tcell
compart
might
detriment
effect
viral
reservoir
light
chloroquinehydroxychloroquin
antireservoir
potenti
view
support
anoth
recent
studi
show
chloroquin
sensit
apoptosi
latent
infect
cell
upon
viral
reactiv
like
remov
antiapoptot
effect
viru
structur
gag
gene
product
effect
potenti
interest
sinc
well
demonstr
viral
reactiv
latenc
necessarili
result
cell
death
macaqu
aid
model
import
tool
preclin
assess
strategi
aim
treat
hivaid
knowledg
chloroquin
test
model
two
occas
first
studi
chloroquin
mg
everi
day
day
ie
cumul
dosag
compar
administ
human
rheumatioid
arthriti
administ
three
chines
rhesu
macaqu
infect
simian
hivhomologu
although
decreas
activ
pdc
shown
effect
seen
viral
load
tcell
activ
measur
express
immun
activ
set
point
establish
acut
infect
vaccari
et
al
treat
chloroquin
mgday
consecut
day
seven
rhesu
macaqu
viral
load
peak
character
acut
infect
apart
unexpect
although
transient
increas
express
interferonregul
gene
perhap
populationrelev
possibl
driven
one
anim
signific
differ
report
viral
load
tcell
activ
prolifer
measur
express
respect
trend
howev
notic
mainten
decreas
level
gut
chloroquinetr
anim
although
differ
valu
control
group
reach
statist
signific
effect
chloroquin
simian
model
presenc
art
still
unknown
chloroquin
hydroxychloroquin
far
test
sever
hiv
clinic
trial
result
summar
figur
support
hypothesi
chloroquinehydroxychloroquin
dosag
may
import
driver
least
partial
clinic
success
suppress
effect
immun
activ
chloroquin
shown
trial
conduct
murray
et
al
howev
trial
dosag
administ
individu
receiv
mgdie
instead
mgdie
thu
possibl
statist
signific
effect
report
studi
driven
higher
dosag
drug
view
support
later
studi
test
chloroquin
mgdie
fail
show
effect
drug
two
clinic
trial
conduct
sperber
et
al
report
suppress
effect
immun
activ
measur
time
product
viral
load
individu
treat
mg
hydroxychloroquineday
bioequival
mgday
chloroquin
clinic
trial
test
hydroxychloroquin
lower
dosag
ie
mgday
led
conflict
result
earlier
studi
recent
studi
piconi
et
al
report
signific
effect
viral
load
count
immun
activ
instead
recent
clinic
trial
random
doubl
blind
show
disappoint
result
even
hint
possibl
deleteri
effect
hydroxychloroquin
viral
load
count
trial
conduct
absenc
art
might
explain
differ
studi
studi
piconi
et
al
conduct
individu
art
anoth
trial
arttreat
patient
current
ongo
provid
inform
effect
hydroxychloroquin
clinicaltrialsgov
identifi
hydroxychloroquin
level
show
high
intersubject
variabl
although
individu
receiv
higher
hydroxychloroquin
dosag
mgday
also
show
significantli
higher
blood
level
drug
receiv
mgdie
rang
blood
concentr
part
overlap
differ
dosag
group
chloroquin
similar
pharmacokinet
therefor
dosag
also
individu
differ
drug
metabol
distribut
may
explain
differ
conclus
aforement
studi
larg
clinic
trial
recent
complet
clinicaltrialsgov
identifi
result
help
better
repres
respons
popul
thu
abolish
bia
due
limit
sampl
size
trial
howev
chloroquin
test
mgday
absenc
art
thu
light
result
aforement
clinic
trial
consider
deriv
basic
scienc
see
next
paragraph
surpris
preliminari
result
releas
far
trial
http
show
signific
effect
chloroquin
immun
activ
viral
load
count
chloroquinehydroxychloroquinetr
individu
display
blood
concentr
highli
variabl
rare
exceed
respect
therefor
steadi
state
level
blood
concentr
part
overlap
therapeut
effect
expect
exampl
chloroquin
pbmc
prolifer
upon
activ
gener
valu
explain
vari
result
obtain
differ
clinic
trial
clearer
effect
associ
higher
drug
dosag
similarli
proapoptot
effect
hydroxychloroquin
memori
tcell
moder
concentr
reachabl
blood
especi
lower
rang
proapoptot
effect
chloroquin
describ
li
et
al
latent
infect
cell
upon
viral
reactiv
instead
mark
although
still
partial
upper
rang
clinic
achiev
blood
concentr
effect
could
therefor
visibl
vivo
term
viral
reservoir
reduct
treat
high
chloroquin
dosag
presenc
suppress
art
moreov
maxim
chanc
obtain
viral
reservoir
reduct
vivo
chloroquin
treatment
prolong
event
viru
reactiv
latenc
rather
rare
estim
one
event
transit
latenc
product
infect
everi
ml
blood
day
effect
chloroquin
pdc
activ
see
figur
initi
observ
vitro
preincub
pdc
chloroquin
h
treatment
result
intracellular
concentr
compar
observ
chronic
vivo
administr
case
vitro
effect
line
result
two
vivo
studi
use
chloroquinerel
compound
increas
potenc
yield
promis
result
vitro
interest
test
bestperform
candid
simian
aid
model
effect
chloroquinehydroxychloroquin
viral
replic
repeatedli
shown
vitro
lower
drug
level
induc
cellular
effect
blood
ratio
howev
much
narrow
shown
antiretrovir
drug
antiretrovir
effect
chloroquinehydroxychloroquin
may
though
becom
visibl
anatom
sanctuari
individu
treat
picontain
antiretrovir
regimen
case
recommend
chloroquinehydroxychloroquin
test
highest
recommend
dosag
futur
hiv
clinic
trial
alternativecomplementari
interpret
result
far
obtain
possibl
exampl
effect
art
regimen
employ
may
play
role
determin
magnitud
effect
observ
follow
chloroquinehydroxichloroquin
addit
studi
piconi
et
al
show
benefit
immunolog
non
respond
may
indic
effect
chloroquin
may
visibl
subset
individu
peculiar
immunolog
characterist
effect
hinder
immunolog
non
homogen
cohort
studi
regard
larger
studi
cohort
stratifi
accord
immunolog
respons
art
could
provid
inform
effect
chloroquinehydroxychloroquin
anoth
open
question
remain
influenc
durat
drug
exposur
shown
chloroquinehydroxychloroquin
cumul
effect
proport
hivinfect
patient
africa
may
alreadi
chloroquin
medic
prevent
malaria
might
worth
examin
longterm
effect
treatment
regard
ongo
phase
iii
clinic
trial
assess
longterm
effect
chloroquin
trimethoprimsulfamethoxazol
phrophylaxi
surviv
diseas
control
hivinfect
individu
suppress
viral
load
good
clinic
respons
art
given
aforement
problem
pharmacokinet
chloroquinehydroxychloroquin
group
chose
follow
differ
yet
partli
similar
approach
corrobor
treatment
hivaid
base
feedback
receiv
basic
scienc
studi
clinic
trial
publish
throughout
year
decid
use
drug
desir
effect
strike
vitro
concentr
lower
trough
plasma
concentr
vivo
also
decid
redirect
research
basi
plasma
concentr
rather
wholeblood
concentr
wide
use
chloroquinehydroxychloroquin
thought
former
might
better
mimic
tissu
cultur
concentr
drug
select
goldbas
compound
auranofin
pharmacodynam
pharmacokinet
well
known
due
decadelong
employ
treatment
rheumatoid
arthriti
main
rational
use
auranofin
studi
abil
target
centraltransit
memori
tcell
compart
figur
known
harbor
main
viral
reservoir
patient
receiv
art
auranofin
drastic
activ
submicromolar
ie
nm
concentr
readili
achiev
human
plasma
administr
auranofin
ultim
led
reduct
viral
reservoir
arttreat
macaqu
review
preclin
studi
recent
publish
reader
address
detail
surprisingli
drug
effect
autoimmun
diseas
rheumatoid
arthriti
auranofin
may
well
benefici
term
reduct
cell
activ
particular
downregul
molecul
induc
auranofin
disrupt
costimulatori
signal
often
crucial
lymphocyt
activ
moreov
apart
memori
tcell
auranofin
also
target
memori
tcell
compart
ie
cellular
subset
known
hyperactiv
hiv
infect
interestingli
describ
hydroxychloroquin
auranofin
shown
disrupt
variou
cell
line
signal
activ
bacteri
lipopolysaccharid
like
constitut
anoth
sourc
immun
hyperactiv
vitro
data
indic
impact
auranofin
lymphocyt
activ
may
mediat
least
part
modul
oxid
stress
note
addit
potent
prooxid
drug
buthionin
sulfoximin
bso
increas
potenc
auranofin
decreas
phytohemagglutinininduc
activ
express
receptor
line
preliminari
data
macaqu
combin
regimen
art
auranofin
bso
induc
function
curelik
condit
follow
suspens
therapi
observ
provid
proof
concept
drastic
decreas
immun
hyperactiv
arrest
siv
diseas
progress
turn
virusimmun
system
balanc
favor
latter
clinic
trial
requir
assess
potenti
auranofin
decreas
immun
activ
arttreat
subject
final
drug
use
propos
treatment
rheumatoid
arthriti
might
find
place
treatment
hivaid
exampl
janu
kinas
inhibitor
tofacitinib
ruxolitinib
shown
promis
vitro
activ
hiv
replic
ongo
vivo
studi
compound
could
provid
opportun
analyz
effect
treatment
viral
replic
immun
activ
